Version 2 2023-09-06, 17:07Version 2 2023-09-06, 17:07
Version 1 2023-08-23, 16:34Version 1 2023-08-23, 16:34
journal contribution
posted on 2023-09-06, 17:07authored byStephanie Wallace, Martin Kartau, Tarun Kakkar, Chris Davis, Agnieszka Szemiel, Iliyana Samardzhieva, Swetha Vijayakrishnan, Sarah Cole, Giuditta De Lorenzo, Emmanuel Maillart, Kevin Gautier, Adrian J. Lapthorn, Arvind H. Patel, Nikolaj Gadegaard, Malcolm Kadodwala, Edward Hutchinson, Affar S. Karimullah
Our growing ability to tailor healthcare to the needs
of individuals
has the potential to transform clinical treatment. However, the measurement
of multiple biomarkers to inform clinical decisions requires rapid,
effective, and affordable diagnostics. Chronic diseases and rapidly
evolving pathogens in a larger population have also escalated the
need for improved diagnostic capabilities. Current chemical diagnostics
are often performed in centralized facilities and are still dependent
on multiple steps, molecular labeling, and detailed analysis, causing
the result turnaround time to be over hours and days. Rapid diagnostic
kits based on lateral flow devices can return results quickly but
are only capable of detecting a handful of pathogens or markers. Herein,
we present the use of disposable plasmonics with chiroptical nanostructures
as a platform for low-cost, label-free optical biosensing with multiplexing
and without the need for flow systems often required in current optical
biosensors. We showcase the detection of SARS-CoV-2 in complex media
as well as an assay for the Norovirus and Zika virus as an early developmental
milestone toward high-throughput, single-step diagnostic kits for
differential diagnosis of multiple respiratory viruses and any other
emerging diagnostic needs. Diagnostics based on this platform, which
we term “disposable plasmonics assays,” would be suitable
for low-cost screening of multiple pathogens or biomarkers in a near-point-of-care
setting.